Aktuellt
SENASTE
Redeye considers Alelion’s Q2’22 report on the weak side as some orders were pushed into the future, even so, sales growth amounted to 36% y/y. Most noteworthy is the strained financial position, as we expect current funds to cover operations for about two quarters.
LÄS MER
